Surface Oncology to Present at Two Upcoming Healthcare Conferences

World News: . []

CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) --  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will be participating and presenting a corporate update at the UBS Global Healthcare Conference on Wednesday, May 22, 2019 at the Grand Hyatt New York in New York City.

Additionally, Dr. Pamela Holland, PhD, vice president of cancer biology, will present at the Brisbane Immunotherapy 2019 Conference.  Her presentation, “Targeting the Adenosine Axis to Treat Cancer” will take place on Friday, May 24, 2019 at the Brisbane Convention Centre, in Brisbane, Australia.

The presentations will be accessible by visiting the Investors page of the website at .

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of six novel immunotherapies and a strategic collaboration with Novartis focused on NZV930 (CD73) and potentially one additional undisclosed program. For more information, please visit .

More news and information about Surface Oncology, Inc.

Published By:

Globe Newswire: 21:00 GMT Wednesday 15th May 2019

Published: .

Search for other references to "surface" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us